Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 33 n° 244

Archive for 9 febbraio 2019

40th Annual Institutional Investors Conference

Posted by fidest press agency su sabato, 9 febbraio 2019

Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the Raymond James 40th Annual Institutional Investors Conference in Orlando, Fla. on Tuesday, March 5, 2019. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 10:25 a.m. Eastern Time. The live webcast of Baxter’s presentation can be accessed at http://www.baxter.com and will be available for replay through April 2, 2019.
Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

2019 BIO CEO & Investor Conference

Posted by fidest press agency su sabato, 9 febbraio 2019

New York Monday, February 11, 2019 3:30pm ET Marriott Marquis (Gramercy room) 2019 BIO CEO & Investor Conference.VenatoRx is a private pharmaceutical company that is focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections. VenatoRx’s lead product, VNRX-5133, is an injectable broad-spectrum beta-lactamase inhibitor (BLI) that directly inhibits all four Ambler classes of beta-lactamases. In addition, VenatoRx has a broad pipeline of preclinical programs, including a broad-spectrum orally bioavailable BLI, a novel class of Penicillin-Binding Protein (PBP) inhibitors that are impervious to beta-lactamase-driven resistance, and novel antiviral agents. By http://www.venatorx.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Incorporate genome sequencing into its consumer health intelligence service

Posted by fidest press agency su sabato, 9 febbraio 2019

Onegevity Health, a new consumer health intelligence company, announced a partnership with Gencove, a leader in genome sequencing and analytics, to incorporate genome sequencing into its consumer health intelligence service.Gencove will provide its cost-effective and scalable low-pass sequencing technology to support Onegevity Health’s multi-omic artificial intelligence (AI) platform, consumer-friendly products, and digital services.
Onegevity Health delivers science-based recommendations for customized nutrition, clinically-studied supplements, and pre- and post-biotics to improve health outcomes. The company’s first product, GutBioTM, combines its advanced Metagenome+TM sequencing technology with AI-based personalized insights and recommendations to help individuals manage and improve gut health. The partnership with Gencove will allow it to expand its offering to include genome sequencing.Onegevity Health was founded by scientific pioneers Drs. Joel Dudley and Chris Mason, along with Thorne CEO Paul Jacobson. The partnership with Thorne will leverage the company’s network of 35,000 physicians. Gencove was founded by leading scientists from the New York Genome Center.Gencove and Onegevity Health also plan to leverage the growing multi-omics database for research and therapeutic development. Compared to other commonly used technologies in direct-to-consumer genomics such as genotyping arrays, Gencove’s low-pass sequencing will integrate whole genome data, which in turn will accelerate research on rare genetic variants and early-stage drug target discovery.
According to Jacobson, “Gencove’s low-pass sequencing technologies provide us with the opportunity to apply genome sequencing at the scale necessary to truly impact population health and also ensure the greatest capacity to integrate future discoveries in all areas of the genome, from known genes to novel non-coding RNAs to regulatory regions, all of which are missed by vendors using arrays or exome capture. Also, genome-microbiome interactions can only truly be modeled by having such integrated data sets from each person.”Joe Pickrell, CEO and co-founder of Gencove, added, “We are excited to support the scientific vision of Onegevity Health and its mission to improve consumer wellness.”

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Silicon Valley Arbitration & Mediation Center 2019 Top Technology Neutrals Announced

Posted by fidest press agency su sabato, 9 febbraio 2019

The Silicon Valley Arbitration & Mediation Center (SVAMC) has released its highly anticipated 2019 List of the World’s Leading Technology Neutrals (the “Tech List”). SVAMC promotes efficient and effective technology dispute resolution, including the use of arbitration and mediation to resolve business disputes. The Tech List named 54 professionals this year.Law firms, corporations, and ADR institutions use the Tech List as a reliable roster of exceptionally experienced and talented neutrals who “get” technology and, just as importantly, possess a deep understanding of the tech business world.The SVAMC Tech List is peer-vetted and includes only the most exceptionally qualified arbitrators and mediators, known for their skill in crafting business-practical legal solutions in the technology sector. Based in key markets in the United States and across the globe, these professionals have collectively handled thousands of successful arbitrations and mediations.All appointees are members of a recognized U.S. or international arbitral or mediation institution panel and are ranked for superior expertise in resolving technology disputes, including technology development and distribution, intellectual property, corporate, finance, trade regulation, aerospace, and other tech sector commercial matters.
The technology sector is not only the main driver of U.S. economic growth, but also makes up a significant portion of the global economy. As the need for alternative dispute resolution (ADR) becomes more apparent in an ever-evolving technology-based society, selecting the right neutral becomes a paramount focus. Some of ADR’s advantages over traditional litigation proceedings include efficiency, cost savings, privacy, enforcement of international judgments, and the ability to select the most qualified decision-maker, rather than relying on courts and juries.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

Oncology Day

Posted by fidest press agency su sabato, 9 febbraio 2019

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the Guggenheim Healthcare Talks Idea Forum Oncology Day on Thursday, February 14, 2019 at 2:00 p.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at http://www.seattlegenetics.com in the Investors section.
Seattle Genetics, Inc. is an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer to make a meaningful difference in people’s lives. ADCETRIS® (brentuximab vedotin) utilizes the company’s industry-leading antibody-drug conjugate (ADC) technology and is currently approved for the treatment of multiple CD30-expressing lymphomas. Beyond ADCETRIS, the company has established a pipeline of novel targeted therapies at various stages of clinical testing, including three in ongoing pivotal trials for solid tumors. Enfortumab vedotin for metastatic urothelial cancer and tisotumab vedotin for metastatic cervical cancer utilize our proprietary ADC technology. Tucatinib, a small molecule tyrosine kinase inhibitor, is in a pivotal trial for HER2-positive metastatic breast cancer. In addition, we are leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents in clinical trials targeting hematologic malignancies and solid tumors. The company is headquartered in Bothell, Washington, and has a European office in Switzerland. For more information on our robust pipeline, visit http://www.seattlegenetics.com and follow @SeattleGenetics on Twitter.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »